aTYR PHARMA INC (ATYR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 4M 8M 12M Q1 '20: 8.5M Q2 '20: 8.6M Q3 '20: 8.5M Q4 '20: 10.5M Q2 '23: 10.4M Q3 '23: 10.7M Q4 '23: 353K Q1 '24: 588K Q2 '24: 588K Q3 '24: 235K Q4 '24: 235K Q1 '25: 0 Q2 '25: 0 Q3 '25: 190K Q4 '25: 190K Q1 '20 Q3 '20 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '21: -30.3M Q4 '21: -34M Q1 '22: -39.2M Q2 '22: -41.3M Q3 '22: -47.1M Q4 '22: -46.4M Q1 '23: -46.8M Q2 '23: -47.8M Q3 '23: -46.9M Q4 '23: -54.9M Q1 '24: -58.8M Q2 '24: -62.5M Q3 '24: -68.1M Q4 '24: -67.9M Q1 '25: -67.1M Q2 '25: -70M Q3 '25: -78.7M Q4 '25: -77.6M Q1 '26: -73.3M Q2 '26: -63.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '21: -30.1M Q4 '21: -33.8M Q1 '22: -38.8M Q2 '22: -40.8M Q3 '22: -46.4M Q4 '22: -45.3M Q1 '23: -45.1M Q2 '23: -45.1M Q3 '23: -43.1M Q4 '23: -50.4M Q1 '24: -53.9M Q2 '24: -57.9M Q3 '24: -63.8M Q4 '24: -64M Q1 '25: -63.4M Q2 '25: -66.6M Q3 '25: -75.1M Q4 '25: -74.1M Q1 '26: -70M Q2 '26: -60.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q3 '21: -30.4M Q4 '21: -33.1M Q1 '22: -37.4M Q2 '22: -38.8M Q3 '22: -39.6M Q4 '22: -41.9M Q1 '23: -32.4M Q2 '23: -35.2M Q3 '23: -32.5M Q4 '23: -33.2M Q1 '24: -55M Q2 '24: -63.5M Q3 '24: -67M Q4 '24: -69.1M Q1 '25: -62.2M Q2 '25: -55.6M Q3 '25: -62.9M Q4 '25: -62M Q1 '26: -59.1M Q2 '26: -54.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q3 '21: -30.6M Q4 '21: -33.3M Q1 '22: -37.6M Q2 '22: -39M Q3 '22: -40.1M Q4 '22: -43.5M Q1 '23: -35.2M Q2 '23: -40.4M Q3 '23: -37.8M Q4 '23: -37.4M Q1 '24: -58M Q2 '24: -64M Q3 '24: -67.1M Q4 '24: -69.2M Q1 '25: -62.2M Q2 '25: -55.7M Q3 '25: -63M Q4 '25: -62.1M Q1 '26: -59.3M Q2 '26: -54.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q1 '19: 2.4M Q1 '20: 6.9M Q1 '21: 14.1M Q2 '21: 16.1M Q3 '21: 18.2M Q1 '22: 27.8M Q2 '22: 28.1M Q3 '22: 28.7M Q1 '23: 41.9M Q2 '23: 55.1M Q3 '23: 57.9M Q1 '24: 66.1M Q2 '24: 72.3M Q3 '24: 75.8M Q1 '25: 86.5M Q2 '25: 90.1M Q3 '25: 97.2M Q1 '26: 98M Q2 '26: 98.1M Q1 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q3 '21: -2.03 Q4 '21: -1.78 Q1 '22: -1.71 Q2 '22: -1.51 Q3 '22: -1.55 Q4 '22: -1.60 Q1 '23: -1.45 Q2 '23: -1.23 Q3 '23: -0.97 Q4 '23: -0.96 Q1 '24: -0.90 Q2 '24: -0.91 Q3 '24: -0.94 Q4 '24: -0.86 Q1 '25: -0.80 Q2 '25: -0.79 Q3 '25: -0.82 Q4 '25: -0.79 Q1 '26: -0.73 Q2 '26: -0.62 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.